Noble Capital analyst Robert LeBoyer initiated coverage of NeuroSense (NRSN) with an Outperform rating and $9 price target Lead product PrimeC has completed two Phase 2 trials for Amyotrophic Lateral Sclerosis and has a Phase 3 trial planned for early 2026, notes the analyst, who adds that initial results from a Phase 2 study in Alzheimer’s disease showed “promising data.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRSN:
- NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC
- NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study
- NeuroSense Therapeutics Approves Resolutions at Annual Meeting
- NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate
- NeuroSense Therapeutics Reports Promising Phase 2b Study Results for ALS Treatment